Abstract

ObjectivesWe aimed to determine the interobserver reproducibility of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) criteria for magnetic resonance imaging in patients on active surveillance (AS) for prostate cancer (PCa) at two different academic centres.MethodsThe PRECISE criteria score the likelihood of clinically significant change over time. The system is a 1-to-5 scale, where 1 or 2 implies regression of a previously visible lesion, 3 denotes stability and 4 or 5 indicates radiological progression. A retrospective analysis of 80 patients (40 from each centre) on AS with a biopsy-confirmed low- or intermediate-risk PCa (i.e. ≤ Gleason 3 + 4 and prostate-specific antigen ≤ 20 ng/ml) and ≥ 2 prostate MR scans was performed. Two blinded radiologists reported all scans independently and scored the likelihood of radiological change (PRECISE score) from the second scan onwards. Cohen’s κ coefficients and percent agreement were computed.ResultsAgreement was substantial both at a per-patient and a per-scan level (κ = 0.71 and 0.61; percent agreement = 79% and 81%, respectively) for each PRECISE score. The agreement was superior (κ = 0.83 and 0.67; percent agreement = 90% and 91%, respectively) when the PRECISE scores were grouped according to the absence/presence of radiological progression (PRECISE 1–3 vs 4–5). Higher inter-reader agreement was observed for the scans performed at University College London (UCL) (κ = 0.81 vs 0.55 on a per-patient level and κ = 0.70 vs 0.48 on a per-scan level, respectively). The discrepancies between institutions were less evident for percent agreement (80% vs 78% and 86% vs 75%, respectively).ConclusionsExpert radiologists achieved substantial reproducibility for the PRECISE scoring system, especially when data were pooled together according to the absence/presence of radiological progression (PRECISE 1–3 vs 4–5).Key Points• Inter-reader agreement between two experienced prostate radiologists using the PRECISE criteria was substantial.• The agreement was higher when the PRECISE scores were grouped according to the absence/presence of radiological progression (i.e. PRECISE 1–3 vs PRECISE 4 and 5).• Higher inter-reader agreement was observed for the scans performed at UCL, but the discrepancies between institutions were less evident for percent agreement.

Highlights

  • In the last decade, active surveillance (AS) has been increasingly used in the management of patients with favourable-risk prostate cancer (PCa), with compliance rates of more than 80% [1]

  • The agreement was higher when the PRECISE scores were grouped according to the absence/presence of radiological progression (i.e. PRECISE 1–3 vs PRECISE 4 and 5)

  • Higher inter-reader agreement was observed for the scans performed at University College London (UCL), but the discrepancies between institutions were less evident for percent agreement

Read more

Summary

Introduction

Active surveillance (AS) has been increasingly used in the management of patients with favourable-risk prostate cancer (PCa), with compliance rates of more than 80% [1]. There is still a lack of consistency in how serial MRI data during AS for PCa should be acquired and reported, either for an individual patient or across different cohorts. In order to address this issue, in 2016, the European School of Oncology convened an international task force of experts in radiology, urology and radiation oncology to make recommendations on MRI reporting during AS. After the 2-day meeting, the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations were outlined [7]. The PRECISE recommendations aimed to define the conduct and reporting of an individual MRI scan and for cohorts of patients with serial MRI scans during AS follow-up [7]

Objectives
Methods
Results
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.